Investigation of Caspase 9 Gene Polymorphism in Patients With Non-small Cell Lung Cancer
- Resource Type
- Authors
- Turgay Isbir; Cigdem Altunok; Sina Ercan; Sibel Arinc; Seda Gulec Yilmaz; Feride Yaman
- Source
- Anticancer Research. 39:2437-2441
- Subject
- Adult
Male
Cancer Research
Genotype
Polymorphism, Single Nucleotide
law.invention
03 medical and health sciences
0302 clinical medicine
Non-small cell lung cancer
Risk Factors
law
Carcinoma, Non-Small-Cell Lung
Humans
Medicine
Genetic Predisposition to Disease
Polymorphism
Allele
Lung cancer
Allele frequency
Alleles
Genetic Association Studies
Polymerase chain reaction
Aged
Caspase-9
biology
business.industry
Heterozygote advantage
General Medicine
Middle Aged
medicine.disease
Caspase 9
respiratory tract diseases
Gene Expression Regulation, Neoplastic
Oncology
030220 oncology & carcinogenesis
Cancer research
biology.protein
Female
Gene polymorphism
business
- Language
- ISSN
- 1791-7530
0250-7005
Background/Aim: Non-small cell lung cancer (NSCLC) is one of the most common forms of lung cancer and the leading cause of cancer-related deaths in the world. Caspase 9 (CASP9) plays a central role in the intrinsic apoptotic pathway. The aim of the study was to investigate the role of caspase 9 gene polymorphism in patients with non-small cell lung cancer. Materials and Methods: The study included 96 NSCLC cases and 67 controls. CASP9 Ex5+32 G>A polymorphism was investigated by real-time polymerase chain reaction. Results: There was a significant difference between the groups in the frequency of CASP9 genotypes (p=0.008). The number of the carriers of the ancestral GG genotype, was significantly higher in the NSCLC group than in the control (p=0.009). The heterozygote GA genotype and mutant A allele frequency were significantly higher in the control group compared to the NSCLC group (p=0.005, p=0.009, respectively). Serum CASP9 levels were significantly lower in the patients group than in the control group (p